THC Therapeutics Acquires The Headquarters Group in Strategic Expansion

Deal News | Jun 24, 2025 | Globenewswire

THC Therapeutics, Inc. has announced the acquisition of The Headquarters Group, Inc. (THG) in an all-share transaction valued at approximately $11 million. This acquisition marks a significant expansion for THCT into the cannabis markets of Oregon and California, bringing under its wing a robust portfolio of businesses in genetics, cultivation, extraction, distribution, real estate, and nutrients. The deal emphasizes THCT's strategy of building a vertically integrated cannabis platform through strategic acquisitions. With decades of experience in the industry, both THC Therapeutics and THG's teams aim to leverage their combined expertise to optimize efficiencies and drive growth, establishing a stronger presence in the U.S. and potential international markets. This acquisition is part of THCT's broader strategy to consolidate leading cannabis companies across key segments, aiming for efficient, scalable growth.

Sectors

  • Cannabis Industry
  • Real Estate

Geography

  • United States – The article discusses activities within the United States, specifically focusing on the cannabis markets in California and Oregon where THC Therapeutics is expanding its operations.
  • West Africa – Mentioned in connection with Harvest Food for Life, one of the acquired subsidiaries, which has opportunities in West Africa with nutrient and fertilizer applications.

Industry

  • Cannabis Industry – The article is primarily about THC Therapeutics, Inc.'s acquisition in the cannabis market. It highlights activities related to cannabis cultivation, extraction, distribution, and the provision of nutrients for cannabis growers.
  • Real Estate – The acquisition includes companies involved in specialty real estate tailored for cannabis cultivation, indicating how real estate plays a crucial role in the operations of cannabis businesses.

Financials

  • $11,000,000 – The total value of THC Therapeutics, Inc.'s acquisition of The Headquarters Group, Inc., conducted through the issuance of Series D Preferred stock.
  • $4.8 million – The combined revenue of the companies under The Headquarters Group, Inc. in 2024.

Participants

NameRoleTypeDescription
THC Therapeutics, Inc.AcquirerCompanyA US public company focusing on acquiring and operating assets within the legal cannabis sector.
The Headquarters Group, Inc.TargetCompanyA holding company with operations in genetics, cultivation, extraction, distribution, and cannabis-focused real estate and nutrients.
Scott CoxCEO of THC Therapeutics Inc.PersonCEO of THC Therapeutics, leading the company's strategic expansion into cannabis markets.
Richard RoweCEO of The Headquarters Group, Inc.PersonCEO of the acquired company, contributing strategic insights on consolidation in the cannabis market.